CLMTCalumet, Inc.
Is the price fair?
A demanding price: priced for a lot of growth and rich vs its sector.
Priced for ~18% a year FCF growth. The price already bakes in strong, sustained growth.
Sector median 18.9× across 51 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CLMT's price assumes
Calumet, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.65× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.0%
Free cash flow yield · Specialty Chemicals median 4.7%
- Growth the price implies
- +18%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- EV / sales
- 1.12
EV / sales
Details›
- EV / EBIToperating margin 1.0%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.12
- Free cash flow, trailing twelve months
- $58M
- Market capitalisation
- $2.99B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Specialty Chemicals
Ranks #31 of 33 by RyuScore